# A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight

> **NCT05209984** · PHASE3 · WITHDRAWN · sponsor: **Eurofarma Laboratorios S.A.**

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg
- **DRUG:** ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg
- **DRUG:** SIB Group Sibus (Sibutramine) 15mg
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT05209984
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-04
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic change in development priorities
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05209984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05209984, "A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05209984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*